2026 Q1 -tulosraportti
Vain PDF
4 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 775 | - | - | ||
| 660 | - | - | ||
| 9 700 | - | - | ||
| 55 | - | - | ||
| 2 654 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 159 929 | 159 929 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 159 929 | 159 929 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenCANTOURAGE GROUP SE O.N. (tip) Cantourage Q1-2026: Profitability breaks through – and a new analyst initiation raises the price target to the highest level to date (Sources: Cantourage Group SE company announcement, May 11, 2026; First Berlin Equity Research initiation of coverage, May 7, 2026) Q1-2026 Highlights – quality over volume - Revenue: EUR 20.6 million (+11.0 % q/q vs. Q4 2025) - EBITDA: EUR 2.2 million with an EBITDA margin of 10.6 % – significant improvement compared to previous quarters - Net cash position: EUR 8.8 million – solid financial platform, still debt-free - Geographical distribution: Germany 51.5 %, UK 41.3 %, Poland 7.3 % The core of these financial results is the margin development. Throughout 2025, Cantourage has streamlined its product portfolio towards premium segments and higher-margin categories, and the effect is now unequivocally visible in the figures. The EBITDA margin of 10.6 % in Q1 is a significant improvement from 6.2 % for full 2025 and documents that the company has moved from pure top-line scaling to a phase of real operational leverage. This is qualitative growth, not quantitative. The UK development is the second big message. With 41.3 % of the group's revenue, the UK is now almost on par with Germany, and as management itself notes, the UK business contributes disproportionately to the group's earnings-performance – i.e., with a higher margin than the group as a whole. This is precisely the pan-European diversification we have talked about, materializing in the figures. New initiation from First Berlin Equity Research – EUR 11 price target On May 7, 2026 – the day before the Q1 figures were published – First Berlin Equity Research initiated coverage of Cantourage with a BUY recommendation and a price target of EUR 11.00, corresponding to an upside of 76.8 % from the level at the time of initiation (EUR 6.22). This is the highest price target to date among analyst houses and surpasses both NuWays (EUR 10) and Montega (EUR 8-10). The interesting thing is that First Berlin did not have the Q1 figures at hand when they set EUR 11 as the target. With today's Q1 print (EBITDA margin 10.6 % in Q1 vs. First Berlin's 2026 estimate of 11.5 %), Cantourage is already ahead of the assumptions behind the valuation. This provides fundamental upside risk to both price target and estimates, not the opposite. First Berlin's central theses are worth highlighting, as they precisely overlap our own analysis: 01) "More than a German flower story" – The market underestimates the company's pan-European platform and continues to price it as a pure regulatory binary in the German market. 02) Capital-light, scalable, debt-free – The DCF model assumes an 80 % equity ratio, 11.1 % WACC, 2 % terminal growth, and 14.8 % terminal EBIT margin. With these assumptions, the fair value lands at EUR 142 million or EUR 11.00 per share. 03) Margin expansion is the next phase – First Berlin expects the EBITDA margin to pass 10 % already in 2026 (as already proven now in Q1-2026), and that the gross margin rebounds from 25.1 % (2025E) to 30.1 % (2026E) and further up towards 33 % over time. Valuation check – current price (before open: market cap approx. EUR 77.3 million) With the Q1 figures and First Berlin's initiation, we now have three analyst houses with a consistent BUY recommendation: First Berlin (initiation, May 7, 2026) sets the price target at EUR 11.00 – an upside of approx. +77 % from the current level. NuWays AG (March 9, 2026) has a price target of EUR 10.00, corresponding to an upside of approx. +61 %. Montega AG (March 9, 2026) is at EUR 8-10, corresponding to an upside of approx. +29-61 %. Our own estimate is at EUR 10-12 per share, corresponding to an upside of approx. +61-93 % from today's level. On the Sanity multiple (~4.2x EV/Sales), Cantourage's FY25 revenue of EUR 92.8 million would justify an EV of approx. EUR 390 million against the current market cap of EUR 77.3 million. Even with appropriate haircuts, the distance between the peer multiple and current pricing is still significant. Sources: - Cantourage Group SE Q1-2026 company announcement, May 11, 2026, 08:00 CET - First Berlin Equity Research, "Cantourage Group SE – More Than A German Flower Story", initiation of coverage, May 7, 2026 (BUY, price target EUR 11.00) - NuWays AG research update on Cantourage, March 9, 2026 (BUY, price target EUR 10.00) - Montega AG research update on Cantourage, March 9, 2026 (BUY, price target EUR 8-10) - Share price Cantourage Group SE (HIGH GR / ISIN DE000A3DSV01), Frankfurt Stock Exchange (market cap approx. EUR 77.3 million before open)
·1 t sittenThis must surely be a good buying opportunity?·1 t sittenWe have been involved since November 2025 and remain very positive about the case. There should definitely be significantly more potential to be gained from the stock with the current multiples, margin-trajectory, and momentum. Our target for the current year remains in the range of EUR 10-12 per share, and this should realistically be possible, provided that the current tendencies, trends, and fundamental momentum continue – and there is currently nothing to suggest the opposite. On the contrary, both the Q1-2026 results, the First Berlin initiation, and the continued M&A activity in the market support our thesis.
·3 päivää sittenDespite strong operational improvements, Stenocare's share price is falling. If one looks a bit closer at the numbers, the picture is more nuanced. Operationally, STENOCARE actually looks stronger than in a long time: revenue up to 3.0m DKK (from 0.78m), EBITDA turned slightly positive, and cash flow from operations actually slightly positive. That is clearly better than last year. But what if one looks at the balance sheet. Only 654k DKK in cash, 1.5m in convertible debt which is now short-term, and over 7m in goodwill. This means that even if operations improve, the financing risk still persists. My interpretation is therefore: The share price drop is less about Q1 operations and more about fear of an emission/refinancing or dilution. Operationally, this looks like progress; financially, it is still tight. I myself am still on the fence until things become clearer. I take that risk. But that is my assessment; it doesn't necessarily have to be the right answer.
3 päivää sitten3 päivää sitten
·3 päivää sittenI am still leaning on the fact that Henrik Elbæk, who is on the board of directors in December 25', bought shares for just over 500.000 kr,- at a price of around 1,39 dkk. I have had Gemini AI look at all his purchases since he joined the board, and from that, it has calculated a GAK of approx. 1,15-1,25 dkk,- with a holding of just over 4,3 mio shares, representing 10% ownership. Please note that Gemini can be wrong.
·3 päivää sittenCan anyone here enlighten me? I have noticed that there have been several trading halts in the Stenocare stock today, even without further decline after reopening and then the halt again after a few minutes? Briefly summarized, what is the logic behind trading halts on the First North exchange in Denmark? (I own shares in Stenocare, even though my holding is hidden) Have a continued good day and journey ahead.·2 päivää sittenThanks 3D for your explanation, it seems the stock is finding its level. I have nothing to buy with and am in it for the long haul, so yesterday's circus doesn't affect me, as I also don't need to sell. Thanks for the information and yes, it makes no sense with these First North stocks that they rise on bad news and fall on good news. Let's hope we've gotten rid of some speculators this time 🙂·2 päivää sittenI would like to, but when there is -5.000 DKK in the budget over the next 12 months, it's not possible. But I have what I have and so far I have bought my first stock without a negative return - now I wait patiently together with other long-term investors and if there's something to buy, I'll buy more 🙂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
4 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenCANTOURAGE GROUP SE O.N. (tip) Cantourage Q1-2026: Profitability breaks through – and a new analyst initiation raises the price target to the highest level to date (Sources: Cantourage Group SE company announcement, May 11, 2026; First Berlin Equity Research initiation of coverage, May 7, 2026) Q1-2026 Highlights – quality over volume - Revenue: EUR 20.6 million (+11.0 % q/q vs. Q4 2025) - EBITDA: EUR 2.2 million with an EBITDA margin of 10.6 % – significant improvement compared to previous quarters - Net cash position: EUR 8.8 million – solid financial platform, still debt-free - Geographical distribution: Germany 51.5 %, UK 41.3 %, Poland 7.3 % The core of these financial results is the margin development. Throughout 2025, Cantourage has streamlined its product portfolio towards premium segments and higher-margin categories, and the effect is now unequivocally visible in the figures. The EBITDA margin of 10.6 % in Q1 is a significant improvement from 6.2 % for full 2025 and documents that the company has moved from pure top-line scaling to a phase of real operational leverage. This is qualitative growth, not quantitative. The UK development is the second big message. With 41.3 % of the group's revenue, the UK is now almost on par with Germany, and as management itself notes, the UK business contributes disproportionately to the group's earnings-performance – i.e., with a higher margin than the group as a whole. This is precisely the pan-European diversification we have talked about, materializing in the figures. New initiation from First Berlin Equity Research – EUR 11 price target On May 7, 2026 – the day before the Q1 figures were published – First Berlin Equity Research initiated coverage of Cantourage with a BUY recommendation and a price target of EUR 11.00, corresponding to an upside of 76.8 % from the level at the time of initiation (EUR 6.22). This is the highest price target to date among analyst houses and surpasses both NuWays (EUR 10) and Montega (EUR 8-10). The interesting thing is that First Berlin did not have the Q1 figures at hand when they set EUR 11 as the target. With today's Q1 print (EBITDA margin 10.6 % in Q1 vs. First Berlin's 2026 estimate of 11.5 %), Cantourage is already ahead of the assumptions behind the valuation. This provides fundamental upside risk to both price target and estimates, not the opposite. First Berlin's central theses are worth highlighting, as they precisely overlap our own analysis: 01) "More than a German flower story" – The market underestimates the company's pan-European platform and continues to price it as a pure regulatory binary in the German market. 02) Capital-light, scalable, debt-free – The DCF model assumes an 80 % equity ratio, 11.1 % WACC, 2 % terminal growth, and 14.8 % terminal EBIT margin. With these assumptions, the fair value lands at EUR 142 million or EUR 11.00 per share. 03) Margin expansion is the next phase – First Berlin expects the EBITDA margin to pass 10 % already in 2026 (as already proven now in Q1-2026), and that the gross margin rebounds from 25.1 % (2025E) to 30.1 % (2026E) and further up towards 33 % over time. Valuation check – current price (before open: market cap approx. EUR 77.3 million) With the Q1 figures and First Berlin's initiation, we now have three analyst houses with a consistent BUY recommendation: First Berlin (initiation, May 7, 2026) sets the price target at EUR 11.00 – an upside of approx. +77 % from the current level. NuWays AG (March 9, 2026) has a price target of EUR 10.00, corresponding to an upside of approx. +61 %. Montega AG (March 9, 2026) is at EUR 8-10, corresponding to an upside of approx. +29-61 %. Our own estimate is at EUR 10-12 per share, corresponding to an upside of approx. +61-93 % from today's level. On the Sanity multiple (~4.2x EV/Sales), Cantourage's FY25 revenue of EUR 92.8 million would justify an EV of approx. EUR 390 million against the current market cap of EUR 77.3 million. Even with appropriate haircuts, the distance between the peer multiple and current pricing is still significant. Sources: - Cantourage Group SE Q1-2026 company announcement, May 11, 2026, 08:00 CET - First Berlin Equity Research, "Cantourage Group SE – More Than A German Flower Story", initiation of coverage, May 7, 2026 (BUY, price target EUR 11.00) - NuWays AG research update on Cantourage, March 9, 2026 (BUY, price target EUR 10.00) - Montega AG research update on Cantourage, March 9, 2026 (BUY, price target EUR 8-10) - Share price Cantourage Group SE (HIGH GR / ISIN DE000A3DSV01), Frankfurt Stock Exchange (market cap approx. EUR 77.3 million before open)·1 t sittenThis must surely be a good buying opportunity?·1 t sittenWe have been involved since November 2025 and remain very positive about the case. There should definitely be significantly more potential to be gained from the stock with the current multiples, margin-trajectory, and momentum. Our target for the current year remains in the range of EUR 10-12 per share, and this should realistically be possible, provided that the current tendencies, trends, and fundamental momentum continue – and there is currently nothing to suggest the opposite. On the contrary, both the Q1-2026 results, the First Berlin initiation, and the continued M&A activity in the market support our thesis.
- ·3 päivää sittenDespite strong operational improvements, Stenocare's share price is falling. If one looks a bit closer at the numbers, the picture is more nuanced. Operationally, STENOCARE actually looks stronger than in a long time: revenue up to 3.0m DKK (from 0.78m), EBITDA turned slightly positive, and cash flow from operations actually slightly positive. That is clearly better than last year. But what if one looks at the balance sheet. Only 654k DKK in cash, 1.5m in convertible debt which is now short-term, and over 7m in goodwill. This means that even if operations improve, the financing risk still persists. My interpretation is therefore: The share price drop is less about Q1 operations and more about fear of an emission/refinancing or dilution. Operationally, this looks like progress; financially, it is still tight. I myself am still on the fence until things become clearer. I take that risk. But that is my assessment; it doesn't necessarily have to be the right answer.
- 3 päivää sitten3 päivää sitten·3 päivää sittenI am still leaning on the fact that Henrik Elbæk, who is on the board of directors in December 25', bought shares for just over 500.000 kr,- at a price of around 1,39 dkk. I have had Gemini AI look at all his purchases since he joined the board, and from that, it has calculated a GAK of approx. 1,15-1,25 dkk,- with a holding of just over 4,3 mio shares, representing 10% ownership. Please note that Gemini can be wrong.
- ·3 päivää sittenCan anyone here enlighten me? I have noticed that there have been several trading halts in the Stenocare stock today, even without further decline after reopening and then the halt again after a few minutes? Briefly summarized, what is the logic behind trading halts on the First North exchange in Denmark? (I own shares in Stenocare, even though my holding is hidden) Have a continued good day and journey ahead.·2 päivää sittenThanks 3D for your explanation, it seems the stock is finding its level. I have nothing to buy with and am in it for the long haul, so yesterday's circus doesn't affect me, as I also don't need to sell. Thanks for the information and yes, it makes no sense with these First North stocks that they rise on bad news and fall on good news. Let's hope we've gotten rid of some speculators this time 🙂·2 päivää sittenI would like to, but when there is -5.000 DKK in the budget over the next 12 months, it's not possible. But I have what I have and so far I have bought my first stock without a negative return - now I wait patiently together with other long-term investors and if there's something to buy, I'll buy more 🙂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 775 | - | - | ||
| 660 | - | - | ||
| 9 700 | - | - | ||
| 55 | - | - | ||
| 2 654 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 159 929 | 159 929 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 159 929 | 159 929 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
4 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenCANTOURAGE GROUP SE O.N. (tip) Cantourage Q1-2026: Profitability breaks through – and a new analyst initiation raises the price target to the highest level to date (Sources: Cantourage Group SE company announcement, May 11, 2026; First Berlin Equity Research initiation of coverage, May 7, 2026) Q1-2026 Highlights – quality over volume - Revenue: EUR 20.6 million (+11.0 % q/q vs. Q4 2025) - EBITDA: EUR 2.2 million with an EBITDA margin of 10.6 % – significant improvement compared to previous quarters - Net cash position: EUR 8.8 million – solid financial platform, still debt-free - Geographical distribution: Germany 51.5 %, UK 41.3 %, Poland 7.3 % The core of these financial results is the margin development. Throughout 2025, Cantourage has streamlined its product portfolio towards premium segments and higher-margin categories, and the effect is now unequivocally visible in the figures. The EBITDA margin of 10.6 % in Q1 is a significant improvement from 6.2 % for full 2025 and documents that the company has moved from pure top-line scaling to a phase of real operational leverage. This is qualitative growth, not quantitative. The UK development is the second big message. With 41.3 % of the group's revenue, the UK is now almost on par with Germany, and as management itself notes, the UK business contributes disproportionately to the group's earnings-performance – i.e., with a higher margin than the group as a whole. This is precisely the pan-European diversification we have talked about, materializing in the figures. New initiation from First Berlin Equity Research – EUR 11 price target On May 7, 2026 – the day before the Q1 figures were published – First Berlin Equity Research initiated coverage of Cantourage with a BUY recommendation and a price target of EUR 11.00, corresponding to an upside of 76.8 % from the level at the time of initiation (EUR 6.22). This is the highest price target to date among analyst houses and surpasses both NuWays (EUR 10) and Montega (EUR 8-10). The interesting thing is that First Berlin did not have the Q1 figures at hand when they set EUR 11 as the target. With today's Q1 print (EBITDA margin 10.6 % in Q1 vs. First Berlin's 2026 estimate of 11.5 %), Cantourage is already ahead of the assumptions behind the valuation. This provides fundamental upside risk to both price target and estimates, not the opposite. First Berlin's central theses are worth highlighting, as they precisely overlap our own analysis: 01) "More than a German flower story" – The market underestimates the company's pan-European platform and continues to price it as a pure regulatory binary in the German market. 02) Capital-light, scalable, debt-free – The DCF model assumes an 80 % equity ratio, 11.1 % WACC, 2 % terminal growth, and 14.8 % terminal EBIT margin. With these assumptions, the fair value lands at EUR 142 million or EUR 11.00 per share. 03) Margin expansion is the next phase – First Berlin expects the EBITDA margin to pass 10 % already in 2026 (as already proven now in Q1-2026), and that the gross margin rebounds from 25.1 % (2025E) to 30.1 % (2026E) and further up towards 33 % over time. Valuation check – current price (before open: market cap approx. EUR 77.3 million) With the Q1 figures and First Berlin's initiation, we now have three analyst houses with a consistent BUY recommendation: First Berlin (initiation, May 7, 2026) sets the price target at EUR 11.00 – an upside of approx. +77 % from the current level. NuWays AG (March 9, 2026) has a price target of EUR 10.00, corresponding to an upside of approx. +61 %. Montega AG (March 9, 2026) is at EUR 8-10, corresponding to an upside of approx. +29-61 %. Our own estimate is at EUR 10-12 per share, corresponding to an upside of approx. +61-93 % from today's level. On the Sanity multiple (~4.2x EV/Sales), Cantourage's FY25 revenue of EUR 92.8 million would justify an EV of approx. EUR 390 million against the current market cap of EUR 77.3 million. Even with appropriate haircuts, the distance between the peer multiple and current pricing is still significant. Sources: - Cantourage Group SE Q1-2026 company announcement, May 11, 2026, 08:00 CET - First Berlin Equity Research, "Cantourage Group SE – More Than A German Flower Story", initiation of coverage, May 7, 2026 (BUY, price target EUR 11.00) - NuWays AG research update on Cantourage, March 9, 2026 (BUY, price target EUR 10.00) - Montega AG research update on Cantourage, March 9, 2026 (BUY, price target EUR 8-10) - Share price Cantourage Group SE (HIGH GR / ISIN DE000A3DSV01), Frankfurt Stock Exchange (market cap approx. EUR 77.3 million before open)·1 t sittenThis must surely be a good buying opportunity?·1 t sittenWe have been involved since November 2025 and remain very positive about the case. There should definitely be significantly more potential to be gained from the stock with the current multiples, margin-trajectory, and momentum. Our target for the current year remains in the range of EUR 10-12 per share, and this should realistically be possible, provided that the current tendencies, trends, and fundamental momentum continue – and there is currently nothing to suggest the opposite. On the contrary, both the Q1-2026 results, the First Berlin initiation, and the continued M&A activity in the market support our thesis.
- ·3 päivää sittenDespite strong operational improvements, Stenocare's share price is falling. If one looks a bit closer at the numbers, the picture is more nuanced. Operationally, STENOCARE actually looks stronger than in a long time: revenue up to 3.0m DKK (from 0.78m), EBITDA turned slightly positive, and cash flow from operations actually slightly positive. That is clearly better than last year. But what if one looks at the balance sheet. Only 654k DKK in cash, 1.5m in convertible debt which is now short-term, and over 7m in goodwill. This means that even if operations improve, the financing risk still persists. My interpretation is therefore: The share price drop is less about Q1 operations and more about fear of an emission/refinancing or dilution. Operationally, this looks like progress; financially, it is still tight. I myself am still on the fence until things become clearer. I take that risk. But that is my assessment; it doesn't necessarily have to be the right answer.
- 3 päivää sitten3 päivää sitten·3 päivää sittenI am still leaning on the fact that Henrik Elbæk, who is on the board of directors in December 25', bought shares for just over 500.000 kr,- at a price of around 1,39 dkk. I have had Gemini AI look at all his purchases since he joined the board, and from that, it has calculated a GAK of approx. 1,15-1,25 dkk,- with a holding of just over 4,3 mio shares, representing 10% ownership. Please note that Gemini can be wrong.
- ·3 päivää sittenCan anyone here enlighten me? I have noticed that there have been several trading halts in the Stenocare stock today, even without further decline after reopening and then the halt again after a few minutes? Briefly summarized, what is the logic behind trading halts on the First North exchange in Denmark? (I own shares in Stenocare, even though my holding is hidden) Have a continued good day and journey ahead.·2 päivää sittenThanks 3D for your explanation, it seems the stock is finding its level. I have nothing to buy with and am in it for the long haul, so yesterday's circus doesn't affect me, as I also don't need to sell. Thanks for the information and yes, it makes no sense with these First North stocks that they rise on bad news and fall on good news. Let's hope we've gotten rid of some speculators this time 🙂·2 päivää sittenI would like to, but when there is -5.000 DKK in the budget over the next 12 months, it's not possible. But I have what I have and so far I have bought my first stock without a negative return - now I wait patiently together with other long-term investors and if there's something to buy, I'll buy more 🙂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 775 | - | - | ||
| 660 | - | - | ||
| 9 700 | - | - | ||
| 55 | - | - | ||
| 2 654 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 159 929 | 159 929 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 159 929 | 159 929 | 0 | 0 |